Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Researchers' data advance breast cancer research
June 30th, 2005
Data on breast cancer are outlined in reports from the United States and United Kingdom. Study 1: The selective estrogen receptor modulator arzoxifene may have therapeutic potential with less toxicity than raloxifene and desmethylated arzoxifene, study findings suggest. "Although selective estrogen receptor modulators (SERMs) are useful in the treatment and prevention of breast cancer, the SERM tamoxifen has been associated with an increased risk of endometrial cancer possibly due to metabolism to electrophilic quinoids. Another SERM, arzoxifene is currently in clinical trials for the treatment of breast cancer, and since it has similar structural...
Source: Women's Health Weekly (2005-06-30)
|
